[Management of secondary hyperparathyroidism].
Cunningham
John
J
The Center for Nephrology, The Royal Free and University College Medial School, London, UK.
D000814:Aniline Compounds / Q000627:therapeutic use*; D002114:Calcinosis / Q000209:etiology / Q000517:prevention & control; D002118:Calcium / Q000097:blood; D000069449:Cinacalcet; D002986:Clinical Trials as Topic; D015195:Drug Design; D004359:Drug Therapy, Combination; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications; D009281:Naphthalenes / Q000627:therapeutic use; D010281:Parathyroid Hormone / Q000097:blood; D010627:Phenethylamines; D010758:Phosphorus / Q000097:blood; D011073:Polyamines / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011437:Propylamines; D044169:Receptors, Calcium-Sensing / Q000819:agonists*; D000069603:Sevelamer; D014652:Vascular Diseases / Q000209:etiology / Q000517:prevention & control; D014807:Vitamin D / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000814:Aniline Compounds; C107873:N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine; D009281:Naphthalenes; D010281:Parathyroid Hormone; D010627:Phenethylamines; D011073:Polyamines; D011437:Propylamines; D044169:Receptors, Calcium-Sensing; D014807:Vitamin D; D010758:Phosphorus; D000069603:Sevelamer; D002118:Calcium; D000069449:Cinacalcet